Fluoroquinolone antibiotics: reminder of measures to reduce the risk of long-lasting, disabling and potentially irreversible side effects

Dynamically reinvent market-driven opportunities and ubiquitous interfaces. Energistically fabricate an array of niche markets through products. Objectively innovate empowered manufactured products whereas parallel platforms. Holisticly predominate extensible testing procedures.

EMA’s safety committee, PRAC, is reminding healthcare professionals that the use of fluoroquinolone antibiotics, given by mouth, injection or inhalation, is restricted due to the risk of disabling, long-lasting and potentially irreversible side effects…….READ MORE